I suspect B2B sales decrease in order to have enough supply for the B2C market. With VesiSorb, Pastilles/Gummies coming to fruition to the market imminently.
Fantastic results, to post a healthy NPAT of $2m whilst rapidly investing substantial amounts into the business production capacity is a testament to management.
Margins increasing substantially is a phenomenal achievement, expecting this number to be closer to 50-55% with vertical brands sales starting up.
New strains on the way, new products, more production capacity and plenty of cash with access to debt if required to continue operations.
I know that there are usually no major movements on news, but surely this profitability and pathway to increased profitability has to have some form of reflection in the SP. At a P/E of 8 and profitability expected to grow, this is a no brainer.
GLTAH (I am very positively skewed here and will digest what negatives to take from it later, but first read is bringing smiles)
- Forums
- ASX - By Stock
- ECS
- Ann: FY24 Results - Record Harvest, Profit and Revenue
Ann: FY24 Results - Record Harvest, Profit and Revenue, page-5
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ECS (ASX) to my watchlist
|
|||||
Last
1.6¢ |
Change
-0.001(3.13%) |
Mkt cap ! $19.97M |
Open | High | Low | Value | Volume |
1.6¢ | 1.6¢ | 1.5¢ | $8.973K | 591.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 3286937 | 1.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.6¢ | 282549 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 3286937 | 0.015 |
12 | 4144556 | 0.014 |
7 | 1353742 | 0.013 |
2 | 1050000 | 0.012 |
2 | 1225000 | 0.011 |
Price($) | Vol. | No. |
---|---|---|
0.016 | 282549 | 3 |
0.017 | 380558 | 4 |
0.018 | 745278 | 5 |
0.019 | 420000 | 3 |
0.020 | 954251 | 8 |
Last trade - 12.02pm 05/09/2024 (20 minute delay) ? |
Featured News
ECS (ASX) Chart |